CONTEXT: Metastatic uveal melanoma recurrence after ≥10 years is not well studied in the clinical literature. This study describes the clinical characteristics and natural history of patients with delayed tumor recurrence. OBJECTIVE: To describe the characteristics of patients with delayed systemic recurrence of uveal melanoma and the natural history of the disease after recurrence. EVIDENCE ACQUISITION: This is a chart review of patients treated between 1994 and 2008 at The University of Texas, MD Anderson Cancer Center for uveal melanoma whose disease recurred ≥10 years after treatment of the primary tumor. RESULTS: Of 463 patients treated for metastatic uveal melanoma, 305 developed systemic recurrence within 5 years from the time of diagnosis of primary melanoma, 97 developed systemic recurrences between 5 and 10 years, whereas 61 patients developed metastasis after ≥10 years. The interval between primary to first systemic metastasis was a significant independent predictor of survival time from first systemic metastasis. The median survival time for patients with delayed metastatic recurrence after ≥10 years was significantly longer than for patients who had intermediate or early systemic recurrence. Levels of lactate dehydrogenase, serum alkaline phosphatase, serum albumin, age, M-stage, and performance status at time of recurrence, as well as sex were also independent predictors of survival time from systemic recurrence. CONCLUSIONS: Longer time interval between primary and first systemic metastasis is significantly correlated with prolonged survival. Patients who survive ≥10 years without tumor metastasis after treatment for primary uveal melanoma cannot be considered cured. Prognosis remains poor for patients with metastatic uveal melanoma.
CONTEXT: Metastatic uveal melanoma recurrence after ≥10 years is not well studied in the clinical literature. This study describes the clinical characteristics and natural history of patients with delayed tumor recurrence. OBJECTIVE: To describe the characteristics of patients with delayed systemic recurrence of uveal melanoma and the natural history of the disease after recurrence. EVIDENCE ACQUISITION: This is a chart review of patients treated between 1994 and 2008 at The University of Texas, MD Anderson Cancer Center for uveal melanoma whose disease recurred ≥10 years after treatment of the primary tumor. RESULTS: Of 463 patients treated for metastatic uveal melanoma, 305 developed systemic recurrence within 5 years from the time of diagnosis of primary melanoma, 97 developed systemic recurrences between 5 and 10 years, whereas 61 patients developed metastasis after ≥10 years. The interval between primary to first systemic metastasis was a significant independent predictor of survival time from first systemic metastasis. The median survival time for patients with delayed metastatic recurrence after ≥10 years was significantly longer than for patients who had intermediate or early systemic recurrence. Levels of lactate dehydrogenase, serum alkaline phosphatase, serum albumin, age, M-stage, and performance status at time of recurrence, as well as sex were also independent predictors of survival time from systemic recurrence. CONCLUSIONS: Longer time interval between primary and first systemic metastasis is significantly correlated with prolonged survival. Patients who survive ≥10 years without tumor metastasis after treatment for primary uveal melanoma cannot be considered cured. Prognosis remains poor for patients with metastatic uveal melanoma.
Authors: Seppo Pyrhönen; Marjo Hahka-Kemppinen; Timo Muhonen; Väinämö Nikkanen; Sebastian Eskelin; Paula Summanen; Ahti Tarkkanen; Tero Kivelä Journal: Cancer Date: 2002-12-01 Impact factor: 6.860
Authors: H M Hurks; J A Metzelaar-Blok; E R Barthen; A H Zwinderman; D De Wolff-Rouendaal; J E Keunen; M J Jager Journal: Invest Ophthalmol Vis Sci Date: 2000-07 Impact factor: 4.799
Authors: Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Donna L Green; Barbara S Hawkins; James Hayman; Ishmael Jaiyesimi; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Jonni Thoma Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Lei Dong; Shuo You; Qing Zhang; Satoru Osuka; Narra S Devi; Stefan Kaluz; Jalisa H Ferguson; Hua Yang; Guoliang Chen; Binghe Wang; Hans E Grossniklaus; Erwin G Van Meir Journal: Clin Cancer Res Date: 2018-12-18 Impact factor: 12.531
Authors: Martin Schneider; Jan Höltje; Uwe Kehler; Volker Hartmann; Konstanze Holl-Ullrich; Katrin Oechel; Peter Paul Urban Journal: J Neurol Date: 2012-12-20 Impact factor: 4.849